Novartis, UCB sign Parkinson's drug deal worth $1.5B


Novartis has partnered with UCB of Belgium in a deal potentially worth $1.5 billion that will focus on co-development and commercialization of two treatments, UCB0599 and UCB7853, which target Parkinson's disease. UCB will receive an upfront payment of $150 million as part of the deal and potential milestone payments worth nearly $1.5 billion.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.